Saniona Investor Relations Material
Saniona AB engages in the research, development, and commercialization of treatments for the central nervous system. The company's products include Tesofensine, a monoamine reuptake inhibitor; Tesomet, a fixed dose combination of tesofensine and metoprolol; SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. Saniona AB (publ) has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS
Marvel-ous Reporting: Marvel’s Comic Inspired Reports
Shareholder reports are often considered tedious and dry. However, in the late 1980s and early 1990s, Marvel Comics revolutionized this perception by transforming its financial reports into captivating comic books.
8 Dec 2023
The Payments Value Chain: A Complex Ecosystem
The payments industry is a complex and dynamic field involving multiple key players. These include customers, merchants, issuers, acquirers, card networks, and various other entities together forming the payments value chain.
8 Dec 2023
NIBE: Creating Millionaires and a Greener Future
NIBE, just like IKEA, was founded in a rural part of Sweden called Småland. The company offers a wide range of pumps, wood stoves, and solar panels.
6 Dec 2023